Expanding Capabilities for Clients: Olon to Open New High Potency API Suite in US

MILAN, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) — Olon Group announces the construction of a cutting-edge High Potency API suite.

A GMP High Potency Active Pharmaceutical Ingredient (HPAPI) suite, currently under construction at the Olon USA site in Concord, Ohio, is the center of excellence for early development of APIs within the Olon Group. This adds to the significant commercial scale expertise and capabilities of the Segrate and Rodano sites near Milan, Italy, and it is part of an important growth of capabilities for handling HPAPI in the group where the company has invested overall around 40 million Euro in the last few years.

Our High Potency API suite is not just a facility; it’s a gateway to new possibilities. Engineered to meet the most stringent safety standards for R&D and GMP processes, this suite will operate for materials with an Occupational Exposure Limit (OEL) of <1 µg/m3 (OEB5, SafeBridge 3). This level of containment is essential for working with materials classified as highly potent, especially in the realm of anti-cancer drugs, where safety is paramount. This is highly integrated with the already existing capability in our Italian sites such as Rodano, to produce highly potent APIs in large-scale product batches ranging from 30 to 150 kg. Today we are one of the few API suppliers to offer the range of specific integrated capabilities necessary to support the customer from the first clinical phase up to industrialization, regardless of the quantity of product needed and batch size required and regardless of the ongoing molecule development phase,” stated Giorgio Bertolini, Senior VP R&D Olon Group.

The High Potency API suite will provide a secure and self-contained environment for working with these materials, ensuring the safety of our operators and staff as they develop the synthetic process or manufacture your clinical grade materials. As additional safety data becomes available, the site can adapt protocols accordingly, allowing scale up for 1-10 µg/m3 OEL (OEB4, SafeBridge 3A) or lower bands into the pilot plant using continuous liner and the portable filter dryer which is rated to OEB5.

www.olonspa.com

Media contact
Sabrina Spina
sspina@olonspa.it – mobile 338.6674289

Staff

Recent Posts

China’s Digital Healthcare Transformation: Local Vendors Lead 2025 EHR Adoption, Highlights Black Book Research

China's healthcare digitalization is being driven by urban innovation, government-backed initiatives, and the dominance of…

5 seconds ago

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or…

11 seconds ago

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

3 hours ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

3 hours ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

3 hours ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

3 hours ago